Secondary Logo

Share this article on:

Therapy With Mesenchymal Stem Cells in Parkinson Disease: History and Perspectives

Mendes Filho, Daniel, MSc*,†; Ribeiro, Patrícia d.C., MSc†,‡; Oliveira, Lucas F., PhD*,§; de Paula, Diógenes R.M., MSc*; Capuano, Vanessa, PhD*; de Assunção, Thaís S.F., MSc‖,¶; da Silva, Valdo J.D., MD, PhD*,‖

doi: 10.1097/NRL.0000000000000188
Review Article

Background: Parkinson disease (PD) is a neurodegenerative disorder affecting the basal nuclei, causing motor and cognitive disorders. Bearing in mind that standard treatments are ineffective in delaying the disease progression, alternative treatments capable of eliminating symptoms and reversing the clinical condition have been sought. Possible alternative treatments include cell therapy, especially with the use of mesenchymal stem cells (MSC).

Review Summary: MSC are adult stem cells which have demonstrated remarkable therapeutic power in parkinsonian animals due to their differentiation competence, migratory capacity and the production of bioactive molecules. This review aims to analyze the main studies involving MSC and PD in more than a decade of studies, addressing their different methodologies and common characteristics, as well as suggesting perspectives on the application of MSC in PD.

Conclusions: The results of MSC therapy in animal models and some clinical trials suggest that such cellular therapy may slow the progression of PD and promote neuroregeneration. However, further research is needed to address the limitations of an eventual clinical application.

Departments of *Physiology, Biological and Natural Sciences Institute

Tropical Medicine and Infectiology, Health Sciences Institute, Triângulo Mineiro Federal University, Uberaba

Nanocell Institute, Divinópolis, MG

Laboratory of Immunology and Experimental Transplantation, São José do Rio Preto Medical School, São José do Rio Preto, SP

§National Institute of Science and Technology for Regenerative Medicine (INCT-REGENERA-CNPq), Rio de Janeiro, RJ

Minas Gerais Network for Tissue Engineering and Cell Therapy (REMETTEC-FAPEMIG), Belo Horizonte, MG, Brazil

The authors declare no conflict of interest.

Reprints: Valdo J.D. da Silva, MD, PhD, Laboratory of Physiology, Triângulo Mineiro Federal University, Biological and Natural Sciences Institute, Praça Manoel Terra, 330, Uberaba CEP 38025-015, MG, Brazil. E-mail: valdo@mednet.com.br.

Parkinson disease (PD), was described in details in 1817 by the English physician James Parkinson in “An Essay on the Shaking Palsy.” It is a neurodegenerative disease caused by a progressive and extensive loss of dopaminergic neurons of the nigrostriatal pathway and loss of neurons in the substantia nigra pars compacta.1 This results in motor signs and symptoms such as postural instability, stiffness (increased muscle tone), bradykinesia, and resting tremor.2,3 In addition to motor symptoms, PD manifests itself in a variety of nonmotor symptoms: neuropsychiatric disorders (like insomnia, anxiety and depression)4,5; autonomic (involving heart rate, blood pressure, urinary bladder, and bowel control)6 and sensory such as olfaction and visual disorders.7,8 Signs and symptoms of PD usually appear around 55 years old2 and when about 80% of the nigrostriatal dopaminergic system is degenerated.9,10

With regards to its epidemiology, PD is one of the most common neurodegenerative diseases,11 affecting about 10 million people globally. This number tends to be increased once the world’s population is aging.12 Because of the growing incidence of the disease, as well as the disadvantages of current treatments, several research groups are striving to develop better treatment options.

The main therapies currently used for PD are deep brain stimulation,13 the use of enzyme inhibitors and levodopa. Such treatments provide symptomatic relief, but they do not reverse the disease progression14 or act efficiently on nonmotor symptoms. Levodopa replacement, currently the main treatment for PD,15 is associated with undesirable side effects like dyskinesia15,16 and impulsive-compulsive behaviors.17 Therefore, increasing efforts are needed for curative and/or more effective treatments.18

In the search for new treatments, many animal experimental models were used, trying to reproduce the symptomatic characteristics of PD and in the attempt to develop new treatments. Mice, rats, and nonhuman primates have commonly been used and exposed to different neurotoxins.1 Among these neurotoxins, the main ones are 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone and 6-hydroxy-dopamine (6-OHDA). The animal models exposed to MPTP allowed to better understand the pathophysiological mechanisms of PD and to develop some of the current treatments against PD.19 MPTP mimics the motor and a wide variety of nonmotor symptoms.20 However, MPTP is not the most reliable model, since the injury caused by this neurotoxin is partial and rodents are less sensitive to its effects.21 In contrast, rotenone can reproduce PD for a longer time by continuous intravenous infusion in the animal.22 However, the frequency in the expression of nonmotor symptoms is low, the sensitivity to rotenone varies according to the animal model and there is a variable sensitivity within the species itself—which makes the use of rotenone a poorly reproducible model.23 Currently, the 6-OHDA-injured rat is the most used PD model as it reproduces the progressive evolution of the disease with adequate motor and nonmotor symptoms (cognitive, behavioral, and gastrointestinal disorders).22,24 At the administration site (usually in the substantia nigra or in the striatum), 6-OHDA accumulates in the cytoplasm of the cells, leading to the generation of reactive oxygen species, cytotoxicity by oxidative stress, and neuroinflammation25—elements observed in the histopathogenesis of PD.26 Many ongoing experimental therapies use animal models in studies with anti-inflammatory drugs,27,28 neurotrophic factors29,30 and alpha-synuclein neutralizers.31,32 In case of cell therapy, neuroregeneration is accompanied by symptomatic relief and few collateral effects.33–35 There is particular attention to the mesenchymal stem cells (MSC) due to their multipotentiality and immunomodulatory properties in cell therapy.36

MSC, also known as mesenchymal stromal cells, were first identified and described by Friedenstein et al.37 These cells are CD73+, CD90+, and CD105+ at their surface—but they do not express CD11b, CD14, CD19, CD79a, CD34, and HLA-DR.36 There are 2 properties that explain MSC’s neuroregenerative potential: their multipotentiality and secretome. Despite controversial existences, many studies describe MSC differentiation in tissue-specific cell type, for example neurons and glial cells.38 Because of their multipotentiality, MSC would be capable of communicating to nearby neurons by new synapses.33 Otherwise, in the context of cell therapy in PD, immunomodulatory and proregenerative paracrine effects of MSC’ secretome are more important than their multipotentiality. In the same way, growing evidences suggest that neuroinflammation would be the main cause of PD pathogenesis.39

Secretome is a group of paracrine factors formed by a large repertory of immunomodulatory cytokines—for example interleukin-6 (IL-6), growth factor beta (TGF-β) and prostaglandin E2 (PGE2)—and trophic factors classified as neurogenics (eg, glial cell derived neurotrophic factor, GDNF), angiogenics, neuroprotectors (eg, brain derived neurotrophic factor, BDNF), and synaptogenics (eg, nerve growing factor, NGF).40–44 These cytokines regulate the intensity of immune response due to the inhibition of cytotoxic T lymphocyte proliferation and stimulation of regulatory T lymphocyte proliferation.45 In contrast, trophic factors can have not only anti-apoptotic and neuroregenerative effects, but they also decrease oxidative stress and stimulate the tissues regeneration.33,36,46–48 For this reason, secretome can limit the neuroinflammatory process and revert its damage at PD.

Another advantage of MSC beyond its therapeutic potential is the diversity of tissues from which they can be extracted: adipose tissue (adMSC), umbilical cord (ucMSC), bone marrow (bmMSC), among others.49,50 Once isolated from their source and cultivated, MSC can be transplanted in differentiated or undifferentiated form.51 However, studies in animal models demonstrated that therapies with previously differentiated MSC are more efficient under certain aspects.33

Another therapeutically important property of MSC is the ability to migrate to sites of injured tissue and inflammation due to signs generated by factors released at these sites.52–54 This migratory competence allows the administration of MSC through many routes in animal models with PD, for example intracerebral, intravenous, and intranasal.48,55–57

Back to Top | Article Outline

FIRST WORKS USING CELL THERAPY WITH MSC IN PD MODELS

In 2001, the work of Li and colleagues was one of the pioneers in the study the therapeutic potential of MSC in PD models. In this work, adult male mice were treated for a week with MPTP hydrochloride (intraperitoneally administered). At the end of this week, undifferentiated bmMSCs were administered into the striatum (intrastriatal) of the mice by stereotaxic surgery. About 1 month after transplantation, the animal’s motor behavior was evaluated using a rotarod test and their brains were extracted for immunohistochemical analysis. In comparison to control mice and untreated parkinsonian mice, the parkinsonian mice treated with bmMSCs presented behavioral recovery and the transplanted cells survived for about a week expressing tyrosine hydroxylase (TH) enzyme immunoreactivity—TH catalyzes catecholamines in a limiting step, so this staining can indicate a dopaminergic cell.58

Dezawa and colleagues (2004) was seeking for a cell therapy that could reduce the progression or even cure PD when they differentiated bmMSC in functional dopaminergic neurons through gene transfection and treatment with trophic factors in rats and humans. These neurons were administered through intrastriatal route and improved motor behavior in parkinsonian rats. Future investigations based on such observations tried to achieve more efficiency with differentiation developing methodologies that did not use gene transfection.59,60 Years later, in 2006, the work of Pacary and colleagues was one of those that demonstrated the viability of the in vitro previous differentiation without using gene transfection. MSC extracted from mice’s bone marrow were treated with cobalt chloride (CoCl2) and Y-27632—which together substantially raised the expression of the EPO and VEGF genes, partially responsible for neurogenesis. Consequently, bmMSC differentiate into neuron-like dopaminergic cells61—the same differentiating effect of CoCl2/Y-27632 treatment was recently demonstrated in rat’s bmMSCs, reproducing, in morphology and cytochemistry, the results of Pacary and colleagues by our group (M.F.D. et al, unpublished data).

Hellmann and colleagues demonstrated that naive MSC and predifferentiated MSC in neuron-like cells can home and regenerate neurodegenerative sites partially. In this study, both naive bmMSC and neuron-like cells were transplanted in parkinsonian rats with lesions at contralateral hemisphere when 6-OHDA was used. Grafted cells migrated through corpus callosum and were distributed to basal nuclei of the opposite hemisphere.62,63

Little was known about the therapeutic mechanisms of MSC action in these parkinsonian models so far. In 2008, Jin et al64 took into account the ability of MSC to produce cytokines—for example NGF and BDNF64,65—and they investigated the effect of these cytokines over other cells in co-culture with rat bmMSC. These cells were co-cultured with ventral mesencephalic cells of rat embryos which are precursors of dopaminergic neurons being suitable for studying dopaminergic neurodegenerative disorders.63,66 As a result, ventral mesencephalic cells increased the expression of tyrosine hydroxylase and expression of dopamine when compared with control group. With that, one beneficial effect of MSC secretome over dopaminergic cells was demonstrated.

Many studies evidenced the therapeutic potential of these paracrine factors and immunomodulatory cytokines, as observed by Kim and colleagues. In vitro and in vivo experiments were performed with the hypothesis that neuroinflammation would be the main cause of nigrostriatal degeneration—and so, the therapeutic effect of MSC would be due to anti-inflammatory cytokines of secretome. In vitro tests, mesencephalic dopaminergic neurons and rat microglia activated by lipopolysaccharide (LPS) were co-cultured with human bmMSC, significantly decreasing the microglial activation, the death rate of neurons, as well as the proinflammatory cytokines in the medium. Likewise, LPS were intranigrally administered in rats and animals transplanted with bmMSC demonstrated less microglial activation and more dopaminergic neurons compared with the control group.67 These results evidenced that the therapeutic potential of MSC in PD are based both on its transdifferentiative capacity and (or maybe even more) on its immunomodulatory competence.

Even secretome having a large contribution to the contention of inflammatory process and neuronal survival, the neuroregeneration of missing nigrostriatal pathway is an indispensable piece for an effective cure of PD. MSC can directly or indirectly promote neuroregeneration (being differentiated in missing neurons). Levy and colleagues studied an example of direct interaction with neuroregeneration using human bmMSC previously differentiated in dopaminergic neuron-like cells intrastriatally administered in the treatment of a parkinsonian rat model (6-OHDA). Besides motor improvement, results of immunocytochemical and immunohistochemical analysis show neuro-like cells with various dopaminergic neuronal markers, integrated into the parenchyma of the striatum in place of degenerate neurons.68

Bahat-Stroomza and colleagues observed the indirect interaction of MSC. They differentiated in vitro human MSC in astrocyte-like cells, being able to produce and release neurotrophic factors—for example BDNF, NGF, and GDNF, which stimulates genesis and neuronal survival. Intrastriatal administration of astrocyte-like cells in rats injured by 6-OHDA improved the motor function. Histologic analysis showed regeneration of dopaminergic pathways. Therefore, MSC differentiated in astrocyte-like cells indirectly promoted neuroregeneration (with neurotrophic factors secreted by them).69

Back to Top | Article Outline

EVOLUTION OF THE RESEARCH

In 2010, Blandini and colleagues transplanted human MSC in animal model with PD. Undifferentiated MSC were injected after 5 days, when 6-OHDA was administered in striatum in rats. After this transplant, MSC survived, integrated in the lesion region and with acquired phenotypic characteristics for neuroglial maturation. In addition, the damage caused by 6-OHDA administration was reduced in animals treated with stem cells. The exact mechanisms involved in such improvement still need to be elucidated in details, but paracrine factors released by MSC, for example GDNF, could represent a way through which such cells exert their therapeutic effect.55,70

Still in 2010, Shi et al71 genetically manipulated MSC in order to express TH or GDNF, which are important for the synthesis and uptake of dopamine in the midbrain, respectively. 6-OHDA was administered in Sprague-Dawley rats through nigrostriatal route and, after the injury was confirmed, genetically modified MSC were transplanted in striatum. Dopamine and GDNF levels were increased in treated animals and an improved PD, as evaluated in behavioral tests, was observed, still more significant for the group that received both types of modified MSC.

In the same context of genetic manipulation, ucMSC were manipulated for expressing VEGF that protects the dopaminergic system.72,73 These cells were transplanted in rats into a rotenone-induced hemiparkinsonian model and differentiated in neuron-like dopaminergic cells, causing therapeutic benefits in animals, such as reduction in apomorphine-induced rotations and emergence of immunoreactivity of TH in the lesion of striatum or substantia nigra.72

Over the following years, several studies were carried out and new knowledge was generated in the area of cell therapy and PD. Among these studies, Cova and colleagues demonstrated that human MSC can cause a protective effect in mouse neural stem cells when in co-culture and exposed to 6-OHDA neurotoxin. This protective effect is possibly originated from the release of cytokines by the MSC, which act in order to avoid neurodegeneration in culture.74

MSC can increase autophagic process of alpha-synuclein degradation, protein which accumulation in neuronal cells is involved in PD.75 When MSC were co-culture with neuronal cells treated with MPP+ (active metabolite of the MPTP toxin), the expression of alpha-synuclein protein decreased and the number of autophagosomes LC3-II+ increased. MSC transplanted in mouse induced by MPTP through caudal vein increased the formation of autophagolysosomes and decreased the expression of alpha-synuclein, indicating that stem cells can contribute for the survival of dopaminergic neurons. In 2014, Capitelli and colleagues used rat model with PD induced by MPTP. They introduced mononuclear cells and bone narrow MSC into the jugular vein as a cell therapy. While mononuclear cells did not cause any benefit, but accelerated the degeneration process of dopaminergic neurons, bmMSC prevented it. This emphasizes the important role of MSC in the prevention of PD.76

Back to Top | Article Outline

RECENT WORKS

Other approaches of MSC in PD include the qualitatively or quantitatively modification of secretome, and their use as carrier of therapeutic substances or even as vector for the transfer of gene fragments to dopaminergic neurons of the basal nuclei.77–79 On the basis of the beneficial effect of the BDNF neurotrophic factor on dopaminergic neurons,80–82 the production of BDNF was increased by bmMSC using genetic engineering. BmMSC were injected on striatum 1 day after the intranigral administration of LPS on rats. In immunohistochemical analysis, it was observed that such MSCs superproducing BNDF protected and regenerated dopaminergic pathways of striatum in situ. However, the nigrostriatal pathway was not fully protected or regenerated.82,83 Mei and Niu used similar methodology, but different results were obtained. They transformed bmMSC into cDNA vectors of conserved dopamine neurotrophic factor (CDNF), which therapeutic effects on dopaminergic neurons have already been described.84 One week after, intrastriatal injection of bmMSC-CDNF, 6-OHDA was infused on rats. The animals treated with these modified MSC (bmMSC-CDNF) had behavioral improvement and more TH+ neurons in nigrostriatal pathway than the control group, which just received undifferentiated bmMSC.83

Schwerk and colleagues used adMSC and got superior results than Hoban82, Mei and Niu.83 AdMSC have late senescence and higher basal rate of neurotrophin secretion than bmMSC, possibly being more efficient in the treatment of neurodegenerative diseases.30,78,85 Schwerk and collaborators injected human adMSC into the substantia nigra of 6-OHDA-injured rats 7 days before. The effects of this cell therapy were assessed 6 months after transplantation. AdMSC promoted cognitive improvements in treated animals, increased the number of dopaminergic neurons in the substantia nigra, interrupted the neuroinflammation, and stimulated subventricular and hippocampal neurogenesis. However, there was no improvement in the motor behavior.78 This suggests that adMSC may be therapeutically more efficient in nonmotor PD symptoms, while bmMSC may be more efficient in motor PD symptoms.

In the same year, Riecke et al86 published a meta-analysis assessing the role of MSCs therapy on behavioral outcomes in animal models of PD. In this work, a systematic search in the literature was performed and 25 studies were included for analysis. PD models were performed on mice or rats by 6-OHDA, MPTP, MG-132, or rotenone induction. In addition, the routes of cell administration were intravenous, intranasal or intrastriatal and the doses of MSCs ranged for each study. After analyzing the data, significant improvement in the behavioral outcomes of animal models of PD was observed. Through the use of meta-regression, it was also possible to conclude that higher doses of MSCs and intravenous administration had greater beneficial effect when considering the limb function tests. The results of this study reaffirm the therapeutic potential of MSCs for PD. In addition, they suggest that the intravenous route is effective, and the intracranial administration more invasive, may not be necessary for cell therapy involving MSCs and PD.

In a different study, Jinfeng et al87 used ucMSC. These MSC were administered over PC12 cells usually used as cellular model for PD. Human ucMSC were previously activated by curcumin—pigment extracted from Curcuma longa, which has anti-inflammatory and anti-apoptotic activity.28,88 PC12 cells were previously incubated with MPP+ for 24 hours. After the administration of ucMSC, the supernatant of PC12 cells had a lower amount of proinflammatory cytokines and NO, but more differentiated dopaminergic neurons, compared with control group—more DAT (dopamine transporter) protein expression, MAP-2, and TH were observed. These results suggest that curcumin-activated ucMSC have neuroprotective effect and induce neuronal differentiation in PC12 and possibly over dopaminergic neurons of basal nuclei of parkinsonian individuals.

Yao et al89 analyzed the therapeutic potential of MSC from another perspective: being enhancers of the regenerative power of neural stem cells (NSCs).90 NSCs can be found in several brain regions and offer a promise for future cell therapies in neurodegenerative conditions and central nervous system damage due to their potential for differentiation.89,91,92 In order to assess the enhancing effect, NSCs from rats were co-cultured in medium containing compounds of MSC secretome from rats, called conditioned medium. Neural stem cells in conditioned medium (NSCs-CM) were transplanted to injured areas, in rats, 28 days after receiving 6-OHDA injection in the medial forebrain and ventral tegmental area. NSCs-CM-treated rats had substantial improvement in motor behavior and spatial learning ability eight weeks post-transplantation, compared to control group. Nevertheless, immunocytochemical and immunohistochemical markings revealed that NSC-CMs survived and differentiated much more in dopaminergic neurons. In addition, these neurons spread throughout the injured regions between medial forebrain and ventral tegmental area and were integrated to them—it explains the motor and cognitive improvements of NSCs-CM treated rats.89

Back to Top | Article Outline

CLINICAL TRIALS

In human beings, the standard treatment to PD is dopamine replacement therapy (L-DOPA or levodopa), which has undesirable effects and the limitation of not delaying the progression of dopaminergic neuronal loss in the substantia nigra. In search for the regeneration of dopaminergic neurons, the encouraging results obtained from the treatment of experimental PD models using mesenchymal stem cells opened the possibility of using this approach in humans.93 Indeed, some clinical trials involving the use of MSCs for the treatment of PD have been developed, but none have shown results so far (Table 1).

TABLE 1

TABLE 1

In a pioneering study conducted in 2010, MSC were transplanted in human patients with PD in a study of Venkataramana and colleagues. The individuals received 1 million of autologous bone marrow stem cells per kilogram of body weight in the sub-lateral ventricular area through stereotaxic surgery. They were followed up for a period of 10 to 36 months and clinical improvement of PD was observed in 3 of 7 individuals, evaluated through classification scale of this disease and quality of life assessment scores [Unified Parkinson Disease Rating Scale—UPDRS, Hoehn and Yahr (H&Y) score, and Schwab and England (S&E) score]. No serious adverse events have been demonstrated. This study was important to encourage the possible therapeutic use of MSC in PD, boosting new researches in this area.94

Two years later, the same author designed a pilot clinical study to determine the safety, feasibility and efficacy of allogenic adult bmMSCs in PD patients. MSCs were obtained from healthy donors, expanded in culture and transplanted at a dose of 2 million cells/kg body weight, into the subventricular zone of patients, who were followed up for 12 months. The results showed improvements in the UPDRS scores of PD patients with no increase in medications during the follow-up period. Besides, they observed that patients in the early stage of PD showed more improvement and no further disease progression than the later stages. It reinforces the idea that bmMSCs transplantation in the early stages of PD has the potential to prevent further progress of the disease. The author pointed out that bmMSCs may be used as therapeutic strategy in the treatment of PD, although more studies must be conducted in order to clarify the long-term safety and sustainability of this treatment, as well the mechanisms of action of these cells in PD patients.94

The establishment of MSC therapy in clinical applications for PD must overcome important challenges before becomes a therapeutic reality, such as issues concerning cell culture conditions, number of cells for transplantation and the better source of MSCs to be clinically used. The success of MSC therapy for PD also involves the standardization of the better route of administration of the cells, patient identification likely to respond to cellular therapy, parameters for cell preparation and delivery to guarantee optimal graft survival, and mechanisms for limiting the immunologic responses to transplanted cells. In conclusion, additional basic and clinical studies will provide further information concerning these issues, contributing to the success of a future MSC therapy for PD.93

Back to Top | Article Outline

CONCLUSIONS

Despite the promising results observed over the years of research, there are still challenges to be overcome for the therapeutic use of MSC, such as finding the most adequate source from which good numbers of cells can be obtained and establishing the best in vitro conditions for the preservation and improvement of all therapeutic properties of these cells.95,96 In any case, studies involving MSC and PD lead to the conclusion that these cells may become usual treatment in the near future. The differentiation competence into various types of neurons demonstrates that MSC can replace dead cells not only in basal nuclei and nigrostriatal pathway, but also in other regions of the parenchyma which degeneration leads to the cognitive and psychiatric symptoms of PD. In contrast, the low immunogenicity and tumorigenicity of MSC reduce possible side effects. As for the secretome, immunomodulatory cytokines and neurotrophic factors reduce neuroinflammation and provide an environment conducive to the survival of the remaining dopaminergic neurons, as well as transdifferentiation of MSC in new neurons. In addition, the migratory capacity of MSC (homing) allows them to be administrated by noninvasive routes or even used as delivery vehicle for molecules of interest. MSC may also have a supporting role in a gene or cell therapy model for PD, enhancing the survival and benefits of other transplanted cells. Consequently, it is reasonable to believe that once the positive results of years of animal experimentation have been widely replicated in humans, MSC may fairly replace (or supplement) current treatments for PD.

Back to Top | Article Outline

ACKNOWLEDGMENT

The authors thank FAPEMIG (Fundação de Apoio a Pesquisa do Estado de Minas Gerais) and CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), agencies of the Minas Gerais State and Brazilian government, for granting MsC fellowships to D.M.F. to P.d.C.R., and D.R.M.d.P., for granting PhD fellowship to T.S.F.d.A., postdoctoral (PNPD/CAPES) fellowship to V.C., and for a financial support grant (PNPD/CAPES-2011-2016) to V.J.D.d.S. The authors also thank CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) for financial support grants (no. 309521/2013-0 and no. 467129/2014-2) to V.J.D.d.S. and to Instituto Nacional de Ciência e Tecnologia em Medicina Regenerativa (INCT-REGENERA, Grant no. 465656/2014-5). The authors would also like to thank Rafael Destro Rosa Tiveron for helping in English language translation.

Back to Top | Article Outline

REFERENCES

1. Hornykiewicz O. Parkinson’s disease: from brain homogenate to treatment. Fed Proc. 1973;32:183–190.
2. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909.
3. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376.
4. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–1649.
5. Breen DP, Vuono R, Nawarathna U, et al. Sleep and circadian rhythm regulation in early Parkinson disease. Jama Neurol. 2014;71:589–595.
6. Kim SR, So HY, Choi E, et al. Influencing effect of non-motor symptom clusters on quality of life in Parkinson’s disease. J Neurol Sci. 2014;347:310–315.
7. Kranick SM, Duda JE. Olfactory dysfunction in Parkinson’s disease. Neurosignals. 2008;16:35–40.
8. Sun L, Zhang H, Gu Z, et al. Stereopsis impairment is associated with decreased color perception and worse motor performance in Parkinson’s disease. Eur J Med Res. 2014;19:29–36.
9. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;120:415–455.
10. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm. 1976;38 (3–4):277–301.
11. Campeau L, Soler R, Sittadjody S, et al. Effects of allogeneic bone marrow derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson disease. J Urol. 2014;191:850–859.
12. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–535.
13. Odekerken VJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12:37–44.
14. Lindvall O, Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson’s disease. Trends Pharmacol Sci. 2009;30:260–267.
15. Porras G, De Deurwaerdere P, Li Q, et al. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci Rep. 2014;4:3730.
16. Heumann R, Moratalla R, Herrero MT, et al. Dyskinesia in Parkinson’s disease: mechanisms and current non-pharmacological interventions. J Neurochem. 2014;130:472–489.
17. Zhang G, Zhang Z, Liu L, et al. Impulsive and compulsive behaviors in Parkinson’s disease. Front Aging Neurosci. 2014;6:318.
18. Salawu F, Olokoba A, Danburam A. Current management of Parkinson’s disease. Ann Afr Med. 2010;9:55–61.
19. Fox SH, Brotchie JM. The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future. Prog Brain Res. 2010;184:133–157.
20. Bezard E, Przedborski S. A tale on animal models of Parkinson’s disease. Mov Disord. 2011;26:993–1002.
21. Speciale SG. MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol Teratol. 2002;24:607–620.
22. Tieu K. A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med. 2011;1:a009316.
23. Hoglinger GU, Féger J, Prigent A, et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem. 2003;84:491–502.
24. Björklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci. 2000;3:537–544.
25. Saner A, Thoenen H. Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol Pharmacol. 1971;7:147–154.
26. Gao HM, Liu B, Zhang W, et al. Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol Sci. 2003;24:395–401.
27. Anusha C, Sumathi T, Joseph LD. Protective role of apigenin on rotenone induced rat model of Parkinson’s disease: suppression of neuroinflammation and oxidative stress mediated apoptosis. Chem Biol Interact. 2017;269:67–79.
28. Tripanichkul W, Jaroensuppapersh EO. Ameliorating effects of curcumin on 6-OHDA-induced dopaminergic denervation, glial response, and SOD1 reduction in the striatum of hemiparkinsonian mice. Eur Rev Med Pharmacol Sci. 2013;17:1360–1368.
29. Hegarty SV, Lee DJ, O’Keeffe GW, et al. Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2017;38:19–25.
30. Izadpanah R, Trygg C, Patel B, et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem. 2006;99:1285–1297.
31. Mandler M, Valera E, Rockenstein E, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener. 2015;10:10.
32. Devine MJ, Gwinn K, Singleton A, et al. Parkinson’s disease and α-synuclein expression. Mov Disord. 2011;26:2160–2168.
33. Glavaski-joksimovic A, Bohn MC. Mesenchymal stem cells and neuroregeneration in Parkinson’s disease. Exp Neurol. 2013;247:25–38.
34. Petit GH, Olsson TT, Brundin P. The future of cell therapies and brain repair: Parkinson’s disease leads the way. Neuropathol Appl Neurobiol. 2014;40:60–70.
35. Takahashi H, Ishikawa H, Tanaka A. Regenerative medicine for Parkinson’s disease using differentiated nerve cells derived from human buccal fat pad stem cells. Hum Cell. 2017;30:60–71.
36. Paul G, Anisimov SV. The secretome of mesenchymal stem cells: potential implications for neuroregeneration. Biochimie. 2013;95:2246–2256.
37. Friedenstein AJ, Piatetzki-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966;16:381–390.
38. Hermann A, Maisel M, Storch A. Epigenetic conversion of human adult bone mesodermal stromal cells into neuroectodermal cell types for replacement therapy of neurodegenerative disorders. Expert Opin Biol Ther. 2006;6:653–670.
39. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37:510–518.
40. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11–15.
41. Chen J, Chopp M. Neurorestorative treatment of stroke: cell and pharmacological approaches. NeuroRx. 2006;3:466–473.
42. Lattanzi W, Geloso MC, Saulnier N, et al. Neurotrophic features of human adipose tissue- derived stromal cells: in vitro and in vivo studies. J Biomed Biotechnol. 2011;2011:468705.
43. Mezey É, Mayer B, Németh K. Unexpected roles for bone marrow stromal cells (or MSCs): a real promise for cellular, but not replacement, therapy. Oral Dis. 2010;16:129–135.
44. Singler NG, Caplan AL. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol. 2011;6:457–478.
45. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–3843.
46. Aizman I, Tate CC, McGrogan M, et al. Extracellular matrix produced by bone marrow stromal cells and by their derivative, SB623 cells, supports neural cell growth. J Neurosci Res. 2009;87:3198–3206.
47. Lu S, Lu C, Han Q, et al. Adipose-derived mesenchymal stem cells protect PC12 cells from glutamate excitotoxicity-induced apoptosis by upregulation of XIAP through PI3-K/Akt activation. Toxicology. 2011;279:189–195.
48. Wang F, Yasuhara T, Shingo T, et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1α. BMC Neurosci. 2010;11:52.
49. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119 (pt 11):2204–2213.
50. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279–4295.
51. Ye M, Wang XJ, Zhang YH, et al. Therapeutic effects of differentiated bone marrow stromal cell transplantation on rat models of Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:44–49.
52. Kang SK, Shin IS, Ko MS, et al. Journey of mesenchymal stem cells for homing: strategies to enhance efficacy and safety of stem cell therapy. Stem Cells Int. 2012;2012:342968.
53. Deng J, Zou ZM, Zhou TL, et al. Bone marrow mesenchymal stem cells can be mobilized into peripheral blood by G-CSF in vivo and integrate into traumatically injured cerebral tissue. Neurol Sci. 2011;32:641–651.
54. Ji JF, He BP, Dheen ST, et al. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells. 2004;22:415–427.
55. Blandini F, Cova L, Armentero MT, et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant. 2010;19:203–217.
56. Danielyan L, Schäfer R, von Ameln-Mayerhofer A, et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 2011;14:3–16.
57. Pavon-Fuentes N, Blanco-Lezcano L, Martínez-Martín L, et al. Stromal cell transplant in the 6-OHDA lesion model. Rev Neurol. 2004;39:326–334.
58. Li Y, Chen J, Wang L, et al. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neurosci Lett. 2001;316:67–70.
59. Dezawa M, Kanno H, Hoshino M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest. 2004;113:1701–1710.
60. Laguna Goya R, Kuan WL, Barker RA. The future of cell therapies in the treatment of Parkinson’s disease. Expert Opin Biol Ther. 2007;7:1487–1498.
61. Pacary E, Legros H, Valable S, et al. Synergistic effects of CoCl2 and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells. J Cell Sci. 2006;119 (pt 13):2667–2678.
62. Hellmann MA, Panet H, Barhum Y, et al. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett. 2006;395:124–128.
63. Picinich SC, Mishra PJ, Mishra PJ, et al. The therapeutic potential of mesenchymal stem cells. Expert Opin Biol Ther. 2007;7:965–973.
64. Jin G, Cho SJ, Choi EG, et al. Rat mesenchymal stem cells increase tyrosine hydroxylase expression and dopamine content in ventral mesencephalic cells in vitro. Cell Biol Int. 2008;32:1433–1438.
65. Garcia R, Aguiar J, Alberti E, et al. Bone marrow stromal cells produce nerve growth factor and glial cell line-derived neurotrophic factors. Biochem Biophys Res Commun. 2004;316:753–754.
66. Munoz JR, Stoutenger BR, Robinson AP, et al. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci U S A. 2005;102:18171–18176.
67. Kim YJ, Park HJ, Lee G, et al. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia. 2009;57:13–23.
68. Levy YS, Bahat-Stroomza M, Barzilay R, et al. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson’s disease. Cytotherapy. 2008;10:340–352.
69. Bahat-Stroomza M, Barhum Y, Levy YS, et al. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s disease. J Mol Neurosci. 2009;39:199–210.
70. Evans JR, Barker RA. Neurotrophic factors as a therapeutic target for Parkinson’s disease. Expert Opin Ther Targets. 2008;12:437–447.
71. Shi D, Chen G, Lv L, et al. The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson’s disease rat model. Neurol Sci. 2011;32:41–51.
72. Xiong N, Zhang Z, Huang J, et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease. Gene Ther. 2011;18:394–402.
73. Tian YY, Tang CJ, Wang JN, et al. Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors. Neurosci Lett. 2007;421:239–244.
74. Cova L, Bossolasco P, Armentero MT, et al. Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson’s disease. Apoptosis. 2012;17:289–304.
75. Park HJ, Shin JY, Kim HN, et al. Neuroprotective effects of mesenchymal stem cells through autophagy modulation in a parkinsonian model. Neurobiol Aging. 2014;35:1920–1928.
76. Capitelli CS, Lopes CS, Alves AC, et al. Opposite effects of bone marrow-derived cells transplantation in MPTP-rat model of Parkinson’s disease: a comparison study of mononuclear and mesenchymal stem cells. Int J Med Sci. 2014;11:1049–1064.
77. Benabdallah BF, Allard E, Yao S, et al. Targeted gene addition to human mesenchymal stromal cells as a cell-based plasma-soluble protein delivery platform. Cytotherapy. 2010;12:394–399.
78. Schwerk A, Altschüler J, Roch M, et al. Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson’s disease. Regen Med. 2015;10:431–446.
79. Rooney GE, McMahon SS, Ritter T, et al. Neurotrophic factor–expressing mesenchymal stem cells survive transplantation into the contused spinal cord without differentiating into neural cells. Tissue Eng Part A. 2009;15:3049–3059.
80. Aoi M, Date I, Tomita S, et al. Single administration of GDNF into the striatum induced protection and repair of the nigrostriatal dopaminergic system in the intrastriatal 6-hydroxydopamine injection model of hemiparkinsonism. Restor Neurol Neurosci. 2000;17:31–38.
81. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130–1132.
82. Hoban DB, Howard L, Dowd E. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson’s disease. Neuroscience. 2015;303:402–411.
83. Mei J, Niu C. Effects of engineered conserved dopamine neurotrophic factor-expressing bone marrow stromal cells on dopaminergic neurons following 6-OHDA administrations. Mol Med Rep. 2015;11:1207–1213.
84. Lindholm P, Voutilainen MH, Laurén J, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature. 2007;448:73–77.
85. Vidal MA, Walker NJ, Napoli E, et al. Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue. Stem Cells Dev. 2012;21:273–283.
86. Riecke J, Johns KM, Cai C, et al. A meta-analysis of mesenchymal stem cells in animal models of Parkinson’s disease. Stem Cells Dev. 2015;24:2082–2090.
87. Jinfeng L, Yunliang W, Xinshan L, et al. Therapeutic effects of CUR-activated human umbilical cord mesenchymal stem cells on 1-methyl-4-phenylpyridine-induced Parkinson’s disease cell model. Biomed Res Int. 2016;2016:9140541.
88. Jaisin Y, Thampithak A, Meesarapee B, et al. Curcumin I protects the dopaminergic cell line SH-SY5Y from 6-hydroxydopamine-induced neurotoxicity through attenuation of p53-mediated apoptosis. Neurosci Lett. 2011;489:192–196.
89. Yao Y, Huang C, Gu P, et al. Combined MSC-secreted factors and neural stem cell transplantation promote functional recovery of PD rats. Cell Transplant. 2016;25:1101–1113.
90. Croft AP, Przyborski SA. Mesenchymal stem cells expressing neural antigens instruct a neurogenic cell fate on neural stem cells. Exp Neurol. 2009;216:329–341.
91. Armstrong RJ, Svendsen CN. Neural stem cells: from cell biology to cell replacement. Cell Transplant. 2000;9:139–152.
92. Fischer I. Candidate cells for transplantation into the injured CNS. Prog Brain Res. 2000;128:253–257.
93. Inden M, Yanagisawa D, Hijioka M, et al. Therapeutic effects of mesenchymal stem cells for Parkinson’s disease. Ann Neurodegener Dis. 2016;1:1002.
94. Venkataramana NK, Pal R, Rao SA, et al. Bilateral transplantation of allogenic adult bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson’s disease: a pilot clinical study. Stem Cells Int. 2012;2012:931902.
95. Trivanović D, Jauković A, Popović B, et al. Mesenchymal stem cells of different origin: comparative evaluation of proliferative capacity, telomere length and pluripotency marker expression. Life Sci. 2015;141:61–73.
96. Kim TE, Lee HS, Lee YB, et al. Sonic hedgehog and FGF8 collaborate to induce dopaminergic phenotypes in the Nurr1-overexpressing neural stem cell. Biochem Biophys Res Commun. 2003;305:1040–1048.
Keywords:

Parkinson disease; mesenchymal stem cells; neurodegenerative disorders; cell therapy; regenerative medicine

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.